Archives
-
Pitavastatin (NK-104) In Vitro Workflow
2026-09-21
Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibitor for controlled studies of cholesterol biosynthesis and related cellular readouts. It is appropriate for exploratory in vitro workflows, but the available dossier does not establish clinical dosing, animal protocols, or a directly matched paper outcome for a specific cardiovascular disease model.
-
TAI-1 Hec1 Inhibitor: Applied Research Workflows
2026-09-21
TAI-1 turns Hec1–Nek2 disruption into a practical workflow for measuring mitotic failure, cancer cell proliferation inhibition, and apoptotic cell death induction. Its strongest value is as a mechanism-led probe for combination studies, RB-aware biomarker testing, and exploratory tumor or organoid models.
-
Pemetrexed A4390: Reliable Cell Assay Design
2026-09-20
This scenario-driven guide explains how Pemetrexed (SKU A4390) can support interpretable cell viability, proliferation, and cytotoxicity experiments. It connects the compound’s multi-target antifolate mechanism with practical stock preparation, exposure design, malignant mesothelioma modeling, and evidence-based product selection.
-
Adipose Remodeling: From Netrin-1 to Translation
2026-09-19
A translational framework for interpreting adipose remodeling, connecting Netrin-1, PPARγ, and Wnt/β-catenin biology with disciplined chemical perturbation strategies using Deoxycholic acid sodium salt.
-
Netrin-1, Adipogenesis, and Metabolic Remodeling
2026-09-18
This Communications Biology study identifies adipose-derived Netrin-1 as a negative regulator of compensatory adipose remodeling during high-fat feeding. Using adipose-specific loss- and gain-of-function models, the authors connect Netrin-1 to impaired PPARγ activity, increased Wnt/β-catenin signaling, and poorer systemic glucose regulation.
-
BRCAness Profiling Predicts PARP Response in Mesothelioma
2026-09-18
Borchert et al. showed that homologous recombination repair gene-expression patterns can stratify malignant pleural mesothelioma for olaparib sensitivity, particularly in BAP1-mutated models. The study supports biomarker-guided combination strategies involving PARP inhibition and cisplatin, while also identifying prognostic HR-related genes for further validation.
-
Sulfaphenazole-Derived Sulfonamides for Tuberculosis
2026-09-17
The reference study systematically optimized sulfaphenazole-derived sulfonamides to preserve activity against Mycobacterium tuberculosis while reducing CYP 2C9 inhibition. Compound 10d emerged as a notable lead, combining a reported MIC of 5.69 μg/mL with CYP 2C9 inhibition above 10 μM and low cytotoxicity, although further pharmacological validation is required.
-
Fenofibrate: PPARα Agonist & YAP Signaling
2026-09-17
Fenofibrate is a PPARα agonist used to investigate lipid metabolism, hepatic remodeling, and cancer biology. Evidence from aging-mouse models indicates that fenofibrate activates the PPARα-YAP signaling axis and induces comparable liver enlargement in adult and aging animals.
-
Foxp1, Notch, and Valvular Calcification in CKD
2026-09-16
A 2026 study identifies endothelial Foxp1 as a regulator of chronic kidney disease-associated valvular calcification, linking repression of the Jagged-1/Notch pathway to reduced endothelial-to-mesenchymal transition and downstream osteogenic activity. The findings provide a mechanistic framework for interpreting endothelial protection and intercellular signaling in CKD-related valve disease, while supporting further investigation of pharmacological strategies that reproduce this regulatory effect.
-
Dextrose in Hypoxia and Immunometabolism
2026-09-16
Dextrose (D-glucose) enables controlled testing of nutrient availability, glycolytic adaptation, and immune–tumor metabolic competition. This workflow combines defined substrate dosing with oxygen-controlled experiments, practical assay design, and troubleshooting for reproducible glucose metabolism research.
-
Calpain Inhibitor I, ALLN: Protocol Guide
2026-09-15
Calpain Inhibitor I, ALLN (SKU A2602) provides a defined cysteine-protease inhibition profile for apoptosis assays, protease-response studies, and ischemia-reperfusion injury research. It should be handled as a research reagent, with model-specific controls and solvent optimization; it is not intended for diagnostic, therapeutic, or medical use.
-
Protein A/G Magnetic Beads for TNBC Validation
2026-09-15
Protein A/G Magnetic Beads provide a practical route to validate the IGF2BP3–FZD1/7 axis in triple-negative breast cancer. This assay-focused guide connects antibody capture, RNA-dependent interactions, co-IP controls, and chromatin workflows to mechanistic interpretation.
-
Pexidartinib: Reading Microglial Assay Signals
2026-09-14
Pexidartinib (PLX3397) offers a selective way to interrogate CSF1R-mediated signaling inhibition across macrophage and microglial models. This article connects a recent seizure-susceptibility study with practical assay design, endpoint selection, and translational limitations.
-
HR Repair Profiling Predicts Olaparib Response in Mesothelio
2026-09-14
Borchert et al. linked homologous recombination repair defects, or BRCAness, with olaparib sensitivity in malignant pleural mesothelioma models. Their combination of cell-based drug testing and clinical-sample gene-expression profiling identifies BAP1-associated vulnerability and candidate prognostic markers, while supporting a rationale for biomarker-guided PARP inhibition.
-
A 6C Culture System for Mouse Corneal Epithelium
2026-09-13
An et al. developed a serum-free, feeder-free 6C culture system that preserves mouse corneal epithelial cell proliferative activity during in vitro expansion and supports epithelial wound repair in vivo. By combining six pathway modulators with air-lift culture, the approach reduced epithelial–mesenchymal transition-associated changes while maintaining progenitor and corneal epithelial markers.